Fidelity Advisor Health Care Fund

Fidelity Advisor Series VII · 5 share classes

Actively managed U.S. equity fund
One fund, 5 share classes:FACDXFHCCXFACTXFHCIXFIKCX
$2.89B NAV
138 positions · as of 2026-04-30 · filed 2026-06-26

Fund classification

Classified from what the fund holds · as of 2026 Q2

Fidelity Advisor Health Care Fund is an actively managed U.S. equity fund.

Asset class
Equity
Region
United States
Management
Actively managed
Fund type
Open-end fund

Fund profile

As filed in the prospectus · 2025 Q3

Fidelity Advisor Health Care Fund seeks capital appreciation.

Strategy · summarised

The fund invests primarily in common stocks of companies principally engaged in health care and medicine, including biotechnology, pharmaceuticals, medical devices and equipment, and health care facilities and managed plans, using fundamental analysis of financial condition, industry position, and market conditions to select holdings. The fund normally maintains at least 80% of assets in health care securities and may invest in both domestic and foreign issuers. As of December 11, 2025, the fund's 80% policy includes derivative instruments providing exposure to health care investments or related market risk factors.

Expenses
0.56% 1.68%across 5 share classes
Share classExpense ratio
FACDX0.93%
FHCCX1.68%
FACTX1.18%
FHCIX0.68%
FIKCX0.56%

Portfolio turnover 52.00% · as of 2025 Q3

Allocation

Asset groups · long / short shown separately, never netted · 2026 Q2

101.41%
of net assets
Stocks99.72%
Cash & short-term1.51%
Bonds0.18%

Sector allocation

The same holdings as Allocation above, grouped by market sector instead of asset type · as of 2026 Q2

100%
of net assets
Health Care84.9%
International11.3%
Other2.3%
Cash1.5%

Government, Securitized and Cash are non-corporate buckets; International is foreign holdings we don’t sector-classify, and Other is the residual (held funds, unresolved names).

Latest quarter

What changed since the fund's previous filing

2026Q2 vs 2026Q1: 24 new20 exited

Largest new: ASCENDIS PHARMA A/S, COR, TECH, VTRS, ROCHE HOLDING AG, NTRA, WST, JAZZ PHARMACEUTICALS PLC

Largest exited: ASCENDIS PHARMA A/S, MASIMO CORP, PEN, IQV, ROCHE HOLDING AG, BIONTECH SE, CENTESSA PHARMACEUTICALS PLC, WAVE LIFE SCIENCES LTD

Return profile

Chart:

Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026

Share class1-year3-year5-yearVolWorst fall
+11.19%-69.27%-93.03%14.34%-73.46%
+10.36%-10.90%-34.84%14.33%-22.49%
+10.91%-48.77%-79.61%14.33%-55.63%
+11.46%+13.91%+7.65%14.34%-13.59%
+11.61%+14.30%+8.34%14.35%-13.54%

These classes hold the same portfolio, so the 101.37pp spread over 5 years is the cost difference between them — roughly 20.27pp a year — not a difference in what they own.

Cumulative return· May 2023 – Apr 2026

Debt profile

What this fund holds — value-weighted across its bond and securitized long positions · as of 2026-04-30

Avg coupon
0.07%
Avg maturity
0.71 yr
Coupon type

Share of the fund's debt by how its coupon behaves — the fact that decides whether a rate move reaches this portfolio at all.

29%
floating
Fixed rate71.2%
Floating rate28.8%
Maturity ladder

Share of the fund's debt value in each maturity band, shortest first.

<1y10y+
<1y71.2%
10y+28.8%
Flagged holdings
Defaulted: none reported
In arrears: none reported
Paid in kind: none reported

Based on what filers reported; a filer that never reported a flag also reads as none.

Holdings

By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page

Issuer%NAVValue
ELI LILLY and COLLY6.93%$200.00M
DANAHER CORPDHR6.79%$195.95M
JOHNSON and JOHNSONJNJ5.67%$163.65M
THERMO FISHER SCIENTIFIC INCTMO3.62%$104.41M
UNITEDHEALTH GROUP INCUNH3.02%$87.06M
BOSTON SCIENTIFIC CORPBSX2.79%$80.65M
ASCENDIS PHARMA A/S2.70%$77.99M
ALNYLAM PHARMACEUTICALS INCALNY2.44%$70.56M
GILEAD SCIENCES INCGILD2.27%$65.42M
ABBVIE INCABBV2.23%$64.24M
Showing 10 of 138Sign in to see more

Reported price is the fund's own reported value divided by its own reported shares at 2026-04-30 — not a live quote, and not what the fund paid.

Top 10 positions are 38.45% of net assets, top 25 59.42%, across 124 issuers.

See more of this fund's book

More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.

Sign in free